A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar® Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephrotic Syndrome due to Idiopathic Membranous Nephropathy (iMN)
Principal Investigator: Vimal Derebail, MD
Sponsor: Questcor Pharmaceuticals, Inc.
Age Range: 18-75
Purpose: The purpose of this research study is to evaluate the safety and effectiveness of the study drug Acthar as compared to Placebo (inactive product) in patients who have been diagnosed with idiopathic nephrotic membranous nephropathy with a low chance of remission who have previously been treated with standard treatment without success. Acthar is a long-approved drug used to treat patients with proteinuria, multiple sclerosis and infantile spasms.
Study Procedures: The drug is given by injection under the skin. The study will include blood draws, 24 hour urine collections, electrocardiogram and vitals
Participation: Participants will be in the study for up to 14 months and 15 visits.
For more information, please contact: